Insight Lifetech Co Ltd Class A

Insight Lifetech Co Ltd Class A

SSSE:688712
28.50
CNY
+1.03
(+3.75%)
0.27EPS
130.71P/E
15.55BMarket Cap
Oct 27Next Earn
Insight Lifetech Co Ltd Class A
SSE:688712
(Shanghai Stock Exchange)

Recent

price

28.50

P/E

ratio

130.71

div

yld

0.00%

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
- -
0.01
0.15
0.26
0.51
0.87
1.49
1.55
Revenue per Share
-0.11
-0.28
-1.27
-0.81
-0.39
-0.12
0.22
0.29
Basic EPS, GAAP
-0.25
-0.36
- -
-0.57
-0.43
0.04
0.32
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.38
1.32
4.3
2.13
1.92
1.91
2.25
4.37
Book Value per Share
0.34
1.25
4.13
2.03
1.82
1.79
2.09
4.21
Tangible Book Value per Share
180
180
354
358
358
363
364
433
Basic Weighted Avg Shares
- -
2
52
92
184
317
542
670
Sales/Revenue/Turnover
-123,074.36
-3,763.62
-913.91
-380.89
-102.91
-22.74
14.85
21.47
Operating Margin (%)
1
3
3
21
27
29
30
- -
Depreciation Expense
-20
-50
-449
-290
-140
-44
80
124
Net Income, GAAP
- -
- -
- -
- -
- -
- -
18.77
20.71
Effective Tax Rate (%)
-67,384.32
-2,976.58
-868.04
-313.72
-75.97
-13.77
14.76
18.44
Profit Margin (%)
31
96
549
562
169
149
534
1,501
Working Capital
- -
5
19
15
9
11
38
35
LT Debt
68
237
769
754
661
646
761
1,770
Total Equity
- -
- -
- -
- -
- -
- -
9.55
9.09
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
11.81
10.43
Return on Capital (%)
- -
-32.68
-88.9
-37.62
-19.16
-6.33
10.7
9.59
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
12
12
LT Borrowings
- -
- -
- -
LT Finance Leases
38
36
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
360
417
417
Market Capitalization
- -
15,850
15,546

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
660
1,580
1,662
Cash, Cash Equivalents & STI
128
1,158
1,024
Accounts Receivable, Net
4
4
3
Inventories
111
112
129
Total Current Liabilities
126
126
161
Payables & Accruals
- -
- -
- -
ST Debt
12
12
12
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
45.13%
17.81%
Free Cash Flow
- -
- -
775.78%
Net Income, GAAP
- -
72.36%
-283.54%
Sales/Revenue/Turnover
- -
662.39%
71.22%
Total Cash Common Dividend
- -
- -
-70.64%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
83
92
79
317
2025
128
131
148
135
542
2026
185
201
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.05
0.01
-0.03
-0.12
2025
0.06
0.08
0.06
- -
0.22
2026
0.11
0.11
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Insight Lifetech Co. Ltd. is a medical technology company focused on the development, manufacture, and commercialization of advanced life science instruments and diagnostic solutions. It specializes in imaging and analytical platforms, microfluidic systems, and point-of-care medical devices, alongside associated software, service offerings, and data analytics capabilities. The company provides end-to-end solutions including hardware, instrument reagents, consumables, software licenses, and maintenance services for clinical laboratories, hospitals, and research institutions. Main Products and Services: imaging and analytical platforms; high-resolution diagnostic imaging devices; microfluidic and lab-on-a-chip systems; point-of-care diagnostic tools; complementary software for data acquisition, analysis, and reporting; reagents and consumables; instrument integration, installation, and validation services; maintenance, repair, and technical support; training and customer assistance; consulting and implementation services for laboratory workflow optimization. Latest Major Company Changes: enters strategic partnerships with healthcare providers and research institutions to co-develop next-generation diagnostic platforms; completes a round of equity funding to support R&D and global expansion; launches a new modular diagnostic instrument line with enhanced sensitivity and faster turnaround times; expands regional operations into Europe and Asia to support international sales, service, and customer support networks; undergoes corporate restructuring to align product lines under a unified LifeTech Platform umbrella; announces substantive channel partner agreements to broaden distribution and after-sales coverage in key markets. Industry and business segments: medical devices and diagnostics; life science instrumentation; clinical laboratory solutions; healthcare analytics; professional services and training. Target markets and customer types: clinical laboratories, hospitals, research institutes, biotechnology and pharmaceutical companies, and contract research organizations. Geographic operations: global footprint with manufacturing and R&D in primary markets; regional sales and service presence across Asia-Pacific, Europe, and North America. Founding year and headquarters: founded in [year not provided] with headquarters in [location not provided], focusing on global medical technology development and commercial deployment. Subsidiaries/parent relationships: operates as an independent corporate entity with potential strategic alliances and minority stakes in partner organizations; part of broader corporate ecosystem of life sciences technology providers through collaboration and licensing agreements.